<div id="readability-page-1"><p>Sensus Healthcare (NASDAQ:SRTS - Get Free Report) posted its quarterly earnings data on Thursday. The company reported ($0.16) earnings per share for the quarter, missing the consensus estimate of ($0.12) by ($0.04), Zacks reports. The firm had revenue of $3.39 million for the quarter, compared to analyst estimates of $5.32 million. Sensus Healthcare had a negative return on equity of 15.11% and a negative net margin of 28.09%.</p><div><p><span></span><span>Get <strong>Sensus Healthcare</strong> alerts:</span></p></div><p>Here are the key takeaways from Sensus Healthcare's conference call:</p><ul>   <li>Sensus says new dedicated <strong>CPT codes</strong> effective Jan 1, 2026 materially improve reimbursement — including about a <strong>300% increase</strong> in the per‑fraction delivery code — and early EOBs show payers are processing claims, which management says is driving stronger physician interest and pipeline growth.</li>   <li>Q1 revenue was $3.4 million versus $8.3 million a year ago primarily because there were no sales to the company's historically largest customer; adjusted EBITDA was negative <strong>$4.2 million</strong> and net loss was <strong>$2.6 million</strong>, though management notes underlying growth when excluding that customer.</li>   <li>Management is prioritizing recurring revenue through the <strong>Sensus Link</strong> software and the Fair Deal/rental program (18 active Fair Deal sites, 9 pending), and highlighted a reimbursable weekly radiation physics code (~$93.85/week) that can be monetized and shared with customers via Sensus Link.</li>   <li>Commercial expansion initiatives — 14 systems shipped in Q1 (10 direct, 4 Fair Deal/rental), ~<strong>70% purchases</strong> of systems in the quarter, the launch of <strong>Sensus Healthcare Financial Services</strong>, and a stronger conference-driven pipeline — underpin management's expectation of higher Q2/H2 revenue and a path to full‑year profitability.</li> </ul><h2>Sensus Healthcare Stock Down 25.1%</h2><p>SRTS stock traded down $1.03 during midday trading on Friday, reaching $3.08. The company's stock had a trading volume of 665,134 shares, compared to its average volume of 84,977. Sensus Healthcare has a 52 week low of $2.82 and a 52 week high of $5.92. The stock has a market cap of $50.70 million, a PE ratio of -6.55 and a beta of 1.19. The business's 50-day simple moving average is $4.14 and its 200-day simple moving average is $4.16. </p><h2>Analyst Ratings Changes</h2><p>Several analysts have recently weighed in on the stock. Wall Street Zen lowered shares of Sensus Healthcare from a &#34;hold&#34; rating to a &#34;sell&#34; rating in a report on Saturday, February 14th. Maxim Group decreased their price target on shares of Sensus Healthcare from $8.00 to $6.00 and set a &#34;buy&#34; rating on the stock in a research note on Tuesday, February 17th. Citigroup  reissued a &#34;buy&#34; rating on shares of Sensus Healthcare in a research note on Friday. Alliance Global Partners assumed coverage on shares of Sensus Healthcare in a research note on Friday, March 6th. They set a &#34;buy&#34; rating and a $7.50 price target on the stock. Finally, Weiss Ratings  reissued a &#34;sell (d)&#34; rating on shares of Sensus Healthcare in a research note on Tuesday, April 21st. Five investment analysts have rated the stock with a Buy rating, one  has given a Hold rating and one  has assigned  a Sell rating to the company's stock. According to MarketBeat, the company presently has a consensus rating of &#34;Moderate Buy&#34; and an average target price of $6.88.</p><p><b>Check Out Our Latest Research Report on Sensus Healthcare</b></p><h2>Hedge Funds Weigh In On Sensus Healthcare</h2><p>A number of hedge funds and other institutional investors have recently bought and sold shares of SRTS. Geode Capital Management LLC boosted its position in shares of  Sensus Healthcare by 2.5% during the second quarter. Geode Capital Management LLC now owns 153,917 shares of the company's stock worth $730,000 after purchasing an additional 3,766 shares in the last quarter.  Jane Street Group LLC bought a new position in shares of  Sensus Healthcare during the fourth quarter worth $79,000.  State Street Corp boosted its position in shares of  Sensus Healthcare by 5.2% during the fourth quarter. State Street Corp now owns 69,252 shares of the company's stock worth $276,000 after purchasing an additional 3,400 shares in the last quarter.  Ingalls &amp; Snyder LLC bought a new position in shares of  Sensus Healthcare during the fourth quarter worth $219,000.  Finally, Greenline Wealth Management LLC bought a new position in shares of  Sensus Healthcare during the fourth quarter worth $513,000. 25.30% of the stock is owned by institutional investors. </p><h2>About Sensus Healthcare</h2> (Get Free Report)<p>Sensus Healthcare, Inc is a medical technology company specializing in the development, manufacture and commercialization of superficial radiation therapy (SRT) systems. The company's SRT devices utilize low-energy X-rays to treat a range of dermatological and oncological conditions, most notably non-melanoma skin cancers such as basal cell carcinoma and squamous cell carcinoma, as well as benign lesions including keloids. By delivering targeted radiation to superficial tissue layers, Sensus Healthcare's systems aim to provide an alternative to surgical excision or systemic therapies, offering clinicians a non-invasive treatment option for eligible patients.  </p><p>The company's flagship products include the SRT-100™ and SRT-100+™ platforms, which feature handheld applicators, adjustable energy settings and integrated safety controls.</p><h2>Read More</h2><ul><li>Five stocks we like better than Sensus Healthcare</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9U1JUUw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="325" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9U1JUUw"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Sensus Healthcare Right Now?</h2><p>Before you consider Sensus Healthcare, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sensus Healthcare wasn't on the list.</p><p>While Sensus Healthcare currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

SRTS

<p>Sensus Healthcare (NASDAQ:SRTS) reported quarterly earnings of ($0.16) EPS, missing estimates by $0.04. Revenue was $3.39 million, below the expected $5.32 million. The company had a negative net margin of 28.09% and a negative return on equity of 15.11%. Despite the disappointing results, management anticipates higher revenue in Q2/H2 due to new reimbursement codes and commercial expansion initiatives. The stock fell 25.1% to $3.08, with analysts rating it as a "Moderate Buy" and a consensus target price of $6.88.</p>

Market Beat

Sensus Healthcare

iShares US Medical Devices

SPDR S&P Health Equip

Citigroup

State Street

CITIGROUP INC 6.250 NON CUM SER II PFD WI

State Street® US Equity Premium Inc ETF

Sensus Healthcare (NASDAQ:SRTS) Releases Quarterly Earnings Results, Misses Expectations By $0.04 EPS